Part VI · Meaning, Evolution, Ethics, and the Future Draft
Chapter 34
Pharmacological Moral Relativism
Moral convictions often arrive with a peculiar phenomenology. They do not feel like preferences. They feel like recognitions.
Cruelty is wrong. Betrayal is wrong. Loyalty matters. Fairness matters. Freedom matters. Some obligations feel self-evident enough that asking for their biological mechanism seems almost insulting.
Yet moral judgment is performed by the same nervous system that performs every other judgment.
If pharmacology can change empathy, harm aversion, patience, aggression, trust, affiliation, dominance, disgust, confidence, reward, and social threat, it should not be surprising if it can also change the intuitions from which moral judgments are built.
This is the descriptive core of pharmacological moral relativism.
The phrase needs immediate qualification. It does not mean that drugs can prove morality is arbitrary. It means that the felt force and weighting of moral considerations may depend partly on biological state.
A person in an affiliative state may care more about interpersonal harmony. A highly threat-sensitive state may prioritize security and loyalty. Strong reward drive may increase the appeal of achievement or autonomy. Reduced aggression can make compromise easier. Increased social salience can deepen attachment to an in-group without improving fairness toward outsiders.
The same pharmacological change can therefore move several moral dimensions at once.
This matters because people often confuse moral change with moral improvement.
Suppose an intervention increases empathy. That sounds desirable. But empathy is selective. People empathize more readily with identifiable individuals, familiar groups, and emotionally vivid stories. Stronger empathy can improve care while biasing decisions away from less salient people. A policymaker overwhelmed by one vivid case may make worse population decisions.
Suppose a drug increases trust. Cooperation may improve. Susceptibility to manipulation may also increase.
Suppose an intervention reduces anger. Violence may fall. So might resistance to genuine injustice.
There is no neurotransmitter setting labeled virtue.
This is one reason the moral-enhancement literature is difficult. To pharmacologically improve morality, one first needs a theory of morality robust enough to specify what improvement means. Increasing one prosocial emotion is not sufficient.
Personality pharmacology contributes a more modest claim: moral cognition has state variables.
This should encourage humility. A conviction that feels self-evident may partly reflect the current weighting of harm, fairness, loyalty, autonomy, disgust, status, or affiliation. Another person with a different temperament may not simply be reasoning badly. They may experience the moral landscape with different salience.
But humility is not nihilism.
We can still evaluate moral systems using consistency, consequences, reciprocity, autonomy, rights, suffering, fairness, and other principles that can be examined across states. The fact that intuitions have causes does not make arguments impossible. Visual perception also has causes, yet we can compare perceptual judgments against the world.
The more interesting question is whether moral judgments remain endorsed across states.
Imagine a person who becomes markedly more affiliative during a pharmacological intervention and then decides to reconcile with someone who has repeatedly harmed them. After the state ends, they regret the decision. Which moral judgment represented their values?
Now imagine the opposite. A psychedelic experience makes someone feel deep concern for animals, and they continue to endorse that concern years later. Was the state merely transient, or did it reveal a value previously suppressed by habit?
Longitudinal endorsement becomes part of the evidence.
The ethical danger of moral pharmacology is coercion. If a state can make people more trusting, patient, compliant, emotionally dampened, or group-oriented, institutions may prefer those traits for reasons unrelated to the person’s flourishing.
A prison might value docility. An employer might value relentless focus. A military might value reduced fear. A partner might value greater attachment. A government might define prosociality as obedience.
The existence of a pharmacological route to those traits makes autonomy more important, not less.
The book therefore needs a strong asymmetry. Voluntary self-modification can be presumptively permissible under conditions of informed consent and acceptable risk. Personality modification imposed by another agent deserves much stricter scrutiny because the intervention can alter the very preferences through which resistance would be expressed.
This is manipulation at the level of the chooser.
The concept of pharmacological moral relativism also connects to culture. Populations differ in temperament distributions, social ecology, threat, institutions, and learned values. Biology does not determine culture, but temperament may change which moral narratives feel compelling, while culture in turn rewards and trains particular temperaments.
The causal arrows are circular.
The most important conclusion is therefore not that morality is chemistry. It is that moral certainty can be state-dependent, and a mature ethics should know this about itself.
That insight leads naturally to a broader question about belief. If entire philosophical or ideological systems become resistant to correction, can they be understood as failures of reality integration even when they are learned rather than psychotic?
The older framework called this “philosophical psychosis”. The next chapter keeps the provocation and tightens the concept.